Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 46-54 , February 2007

Advances in Hormonal Therapy for Breast Cancer

  • Nancy Jo Bush

      Affiliations

    • Corresponding Author InformationAddress correspondence to Nancy Jo Bush, RN, MN, MA, AOCN®, Premiere Oncology, 2020 Santa Monica Blvd, Suite 510, Santa Monica, CA 90404

References 

  1. Kudchadkar R, O’Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin. 2005;55:145–163
  2. Johansen AM. Breast cancer chemoprevention: a review of selective estrogen receptor modulators. Clin J Oncol Nurs. 2005;9:317–320
  3. Major MA. Medical management of advanced breast cancer. Cancer Nurs. 2003;26(suppl 6):10S–15S
  4. Carlson RW, Brown E, Burstein HJ, et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Cancer Netw. 2006;4(suppl 1):S1–S26
  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet. 2005;365:1687–1717
  6. National Comprehensive Cancer Network. Practice guidelines in oncology—invasive breast cancer. Version 2.2006. Available at http://www.nccn.org. (accessed September 1, 2006).
  7. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001;30:44–51
  8. Harwood KV. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. Clin J Oncol Nurs. 2004;8:629–637
  9. Wilkes GM, Barton-Burke M. Oncology Nursing Drug Handbook. 2006;Boston. MA: Jones and Bartlett: 2006.
  10. Grana G. New developments in endocrine therapy: role of adjuvant therapy for early breast cancer. Cancer Nurs. 2003;26(suppl 6):4S–9S
  11. Viale PH. Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment. Oncol Nurs Forum. 2005;32:343–351
  12. Gerken P. Toremifene citrate (Fareston). Clin J Oncol Nurs. 2004;8:529–530
  13. STAR Clinical Trial Summary. www.cancer.gov/newscenter/pressreleases/STARresults. (accessed September 1, 2006).
  14. Palmieri FM, Perez EA. Recent advances in adjuvant therapy for breast cancer. Semin Oncol Nurs. 2003;19(suppl 2):10–16
  15. Colozza M, de Azambuja E, Cardosa F, et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist. 2006;11:111–125
  16. Al-Hajj A, O’Regan R. Selection of optimal adjuvant endocrine therapy for early-stage breast cancer. Curr Treat Options Oncol. 2006;7:153–165
  17. Jonat G, Hilper F. Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects. J Cancer Res Clin Oncol. 2006;132:343–355
  18. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  19. Ingle JN. Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res. 2006;12:1031s–1036s
  20. Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res. 2006;12:1037s–1048s
  21. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  22. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–5147
  23. Coombs RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  24. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2-3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24:910–917
  25. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–690
  26. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802
  27. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271
  28. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006;99:295–300
  29. Goss PE. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol. 2006;33(suppl 7):S8–S12
  30. Tuma RS. San Antonio Breast Cancer Symposium: aromatase inhibitors decrease breast cancer recurrence even after treatment hiatus. Oncol Times. 2006;28(5):22–26
  31. Howell A. Fulvestrant (‘faslodex’): current and future role in breast cancer management. Crit Rev Oncol Hematol. 2006;57:265–273
  32. Monnier A. The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98. Breast. 2006;15(suppl 1):21–29
  33. Bhatnagar AS. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting. Breast. 2006;15(suppl 1):3–13
  34. Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. www.ncbi.nim.nih.gov. (accessed April 17, 2006).
  35. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–629
  36. Ganz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am J Med. 2005;118(suppl 2):136–141
  37. Knopf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist. 2006;11:96–110
  38. Grana G. Adjuvant aromatase inhibitor therapy for early breast cancer: a review of the most recent data. J Surg Oncol. 2006;93:585–592

PII: S0749-2081(06)00161-6

doi: 10.1016/j.soncn.2006.11.008

Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 46-54 , February 2007

Article Tools